Tumors in animal models, mostly mice, are usually very “young” and immature. We inject cancerous cells in matrigell and start administering nanoparticles within the next few days or a week. In the case of human, cancer grows sometimes for many years, so cancer vascular system is much more developed and matured. Can we then compare passive (EPR) targeting in mice and humans? Are there any indisputable published data which proves EPR (based on nano size only) effect in humans?